Safety and metabolic advantages of steroid withdrawal after 6 months posttransplant in de novo kidney transplantation: A 1‐year prospective cohort study

• Published in: Immunity, Inflammation and Disease Inflammation and Disease, 2022-03, Vol.10 (3), p.e576-n/a
• Main Authors: Bang, Jun B., Oh, Chang‐Kwon, Kim, Yu S., Kim, Sung H., Yu, Hee C., Kim, Chan‐Duck, Ju, Man Ki, So, Byung J., Lee, Sang Ho, Han, Sang Y., Jung, Cheol W., Kim, Joong K., Ahn, Hyung J., Lee, Su H., Jeon, Ja Y.
• Format: Article
• Language: English
• Subjects: Biopsy; cholesterol; Cohort analysis; Creatinine; Diabetes; Drug dosages; Glucose; glucose tolerance test; Hypertension; Immunology; Insulin; Kidney diseases; kidney transplantation; Kidney transplants; Laboratories; Metabolism; Original; Patients; Performance evaluation; Plasma; Population; Steroids
• ISSN: 2050-4527; 2050-4527
• DOI: 10.1002/iid3.576

Introduction This prospective multicenter study aimed at investigating the safety and metabolic advantages of steroid withdrawal (SW) therapy in kidney transplant recipients with tacrolimus–mycophenolate mofetil‐based immunosuppression. Methods We analyzed 179 recipients who received kidney transplantation from March 2016 and September 2018. In 179 recipients, 114 patients maintained an immunosuppressive regimen including steroids (steroid continuation [SC] group). The remaining 65 patients were determined to withdraw steroid therapy after 6 months posttransplant (SW group). Metabolic parameters and graft functions of the two groups were evaluated. Results The estimated glomerular filtration rates at 12 months posttransplant were 67.29 ± 20.29 ml/min/1.73 m2 in SC group and 73.72 ± 17.57 ml/min/1.73 m2 in SW group (p